Pomalidomide-PEG4-Ph-NH2 is an advanced E3 ligase ligand-linker conjugate designed for use in PROTAC (Proteolysis Targeting Chimera) drug discovery and development. This bifunctional molecule features a pomalidomide moiety, which serves as a cereblon (CRBN) E3 ubiquitin ligase recruiting ligand, conjugated via a polyethylene glycol (PEG4) linker to a terminal aniline (Ph-NH2) group. The PEG4 spacer enhances the flexibility and solubility of the molecule, facilitating optimal spatial arrangement for efficient target protein degradation.
Structure of 1818885-63-0
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Pomalidomide-PEG4-Ph-NH2 is a specialized E3 ligase ligand-linker conjugate commonly used in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras). This bifunctional molecule features pomalidomide—a derivative of thalidomide known to recruit the cereblon (CRBN) E3 ubiquitin ligase—attached via a PEG4 (polyethylene glycol tetramer) linker to a terminal amine-functionalized phenyl ring. Its structure allows for modular attachment to small-molecule warheads, enabling targeted protein degradation. As interest in targeted protein degradation continues to rise, Pomalidomide-PEG4-Ph-NH2 plays a pivotal role in expanding the possibilities of novel drug discovery.
Mechanism
Pomalidomide-PEG4-Ph-NH2 operates by leveraging the PROTAC technology platform. The pomalidomide moiety acts as a CRBN E3 ligase ligand, specifically binding to the CRBN complex. The PEG4 spacer provides optimal flexibility and solubility, minimizing steric hindrance while maintaining appropriate distance between the two binding domains. The terminal aminophenyl group acts as a handle for conjugation to a variety of ligands that target a protein of interest (POI). Once a PROTAC is synthesized using this intermediate, it can simultaneously bind the target protein and CRBN, bringing them into proximity and facilitating ubiquitination and subsequent proteasomal degradation of the POI.
Applications
Pomalidomide-PEG4-Ph-NH2 is primarily utilized as a building block in the synthesis of PROTAC molecules for protein degradation studies. Its applications span target validation, drug discovery, and the development of new chemical probes for undruggable proteins. Researchers use this conjugate to design PROTACs aimed at degrading disease-associated proteins in oncology, immunology, and neuroscience. Additionally, the PEG4 linker enhances aqueous solubility and pharmacokinetic properties, making it suitable for both in vitro cellular assays and in vivo preclinical studies. The amine terminus allows for customizable conjugation via amide or urea bond formation with diverse targeting ligands, facilitating rapid SAR (structure-activity relationship) studies.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.